Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Operating Expenses (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Operating Expenses for 7 consecutive years, with $10.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 81.91% to $10.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.6 million through Dec 2025, up 67.58% year-over-year, with the annual reading at $43.6 million for FY2025, 67.58% up from the prior year.
  • Operating Expenses hit $10.6 million in Q4 2025 for Eton Pharmaceuticals, up from $9.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $13.4 million in Q2 2025 to a low of $4.4 million in Q4 2021.
  • Historically, Operating Expenses has averaged $6.7 million across 5 years, with a median of $5.8 million in 2024.
  • Biggest five-year swings in Operating Expenses: crashed 44.31% in 2021 and later skyrocketed 81.91% in 2025.
  • Year by year, Operating Expenses stood at $4.4 million in 2021, then increased by 20.22% to $5.3 million in 2022, then grew by 6.13% to $5.6 million in 2023, then increased by 3.98% to $5.8 million in 2024, then surged by 81.91% to $10.6 million in 2025.
  • Business Quant data shows Operating Expenses for ETON at $10.6 million in Q4 2025, $9.2 million in Q3 2025, and $13.4 million in Q2 2025.